Subject(s)
Adjuvants, Immunologic/pharmacology , Aflatoxin B1/toxicity , Amino Acids/pharmacology , Benzene/toxicity , Peptides/pharmacology , Animals , Cell Death/drug effects , Chickens , In Vitro Techniques , Male , Mice , Mice, Inbred CBA , Spleen/cytology , Spleen/drug effects , Spleen/immunologySubject(s)
Aflatoxin B1/poisoning , Benzene/poisoning , Granulocytes/drug effects , Mycotoxicosis/immunology , Phagocytosis/drug effects , Amino Acids/immunology , Amino Acids/pharmacology , Animals , Chickens , Chronic Disease , Glutamic Acid/immunology , Glutamic Acid/pharmacology , Granulocytes/immunology , Male , Mice , Mice, Inbred CBA , Phagocytosis/immunologySubject(s)
Antibody-Producing Cells/drug effects , Apolipoproteins B/immunology , Lipoproteins, HDL/pharmacology , Lipoproteins, LDL/pharmacology , Phagocytosis/drug effects , Adjuvants, Immunologic/pharmacology , Animals , Antibody-Producing Cells/immunology , Cell Death/drug effects , Cell Death/immunology , Humans , Immunosuppressive Agents/pharmacology , Lipid Peroxidation/immunology , Lipoproteins, HDL/chemistry , Lipoproteins, HDL/immunology , Lipoproteins, LDL/chemistry , Lipoproteins, LDL/immunology , Male , Mice , Mice, Inbred CBA , Neutrophils/drug effects , Neutrophils/immunology , Oxidation-Reduction , Peritoneal Cavity/cytology , Phagocytosis/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/immunologySubject(s)
Adjuvants, Immunologic/administration & dosage , Aflatoxin B1/administration & dosage , Benzene/administration & dosage , Phagocytosis/drug effects , Animals , Antibody-Producing Cells/drug effects , Antibody-Producing Cells/immunology , Antigens, Surface/drug effects , Antigens, Surface/immunology , Bone Marrow/drug effects , Bone Marrow/immunology , Dose-Response Relationship, Drug , Immunization , Male , Membrane Glycoproteins/drug effects , Membrane Glycoproteins/immunology , Mice , Mice, Inbred CBA , Spleen/drug effects , Spleen/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Thy-1 AntigensABSTRACT
Immunostimulating properties of cholecystokinin octapeptide (CCK-8) were evaluated in experiments on adult normal and thymectomized mice, in vitro. It was shown that CCK-8 stimulates IgM-PFC production to SRBC, but does not change the immune response to Vi-antigen. CCK-8 increases the number of Thy-I+ spleen T cells and restores thymus-dependent immune response in thymectomized mice. CCK-8 has no effect on neutrophil phagocytosis activity in vitro. The immunostimulating activity of CCK-8 is related mainly to C-terminal fragment (identical to pentagastrin tetrapeptide) since the N-terminal CCK-8 tetrapeptide displays negligible effect in all tests.
Subject(s)
Adjuvants, Immunologic/pharmacology , Peptide Fragments/pharmacology , Sincalide/pharmacology , Animals , Dose-Response Relationship, Drug , Erythrocytes/drug effects , Erythrocytes/immunology , Male , Mice , Mice, Inbred CBA , Phagocytosis/drug effects , Spleen/drug effects , Spleen/immunology , Structure-Activity Relationship , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , ThymectomyABSTRACT
In experiments on mice and in vitro the influence of neurotensin pentagastrin and thymopentin on the immune response, the phagocytosis of staphylococcus aureus by polymorphoneutrophil leucocytes and enzymatic activity of these cells by NBT-test were investigated. It was shown that neurotensin and thymopentin increase enzymatic and phagocytic function of polymorphoneutrophil leucocytes. Pentagastrin, as well as thymopentin stimulates the immune response, enzymatic but not phagocytic function of polymorphoneutrophil leucocytes. Immunostimulating effect of the studied peptides was realized by facility differentiation of mouse bone marrow cells into T-lymphocytes and by the interaction of the peptides with T-cells.
Subject(s)
Adjuvants, Immunologic/pharmacology , Neurotensin/pharmacology , Neutrophils/immunology , Pentagastrin/pharmacology , Peptide Fragments/pharmacology , Phagocytosis , Thymopoietins/pharmacology , Thymus Hormones/pharmacology , Animals , In Vitro Techniques , Male , Mice , Mice, Inbred CBA , Neutrophils/drug effects , Staphylococcus aureus , ThymopentinABSTRACT
It has been shown that study of immunopathological component in acute pneumonias is of value. Such an approach has demonstrated that in the course of the disease there form immune complexes (IC), which absorb complement and are of importance for the disease pathogenesis, and tissue immune complexes which do not absorb complement. Formation of anticomplement IC in acute pneumonias is in a good agreement with a reduction in blood serum complement level with a concurrent change in these indicators in the lungs. The demonstration of anticomplement IC in patients with acute pneumonia has a prognostic value. The stay at hospital of the patients who demonstrated IC at the very beginning of the disease was 2.5 times longer because of the lack of the process normalization.
Subject(s)
Antigen-Antibody Complex/analysis , Complement System Proteins/analysis , Pneumonia/immunology , Acute Disease , Autoantigens/analysis , Complement Inactivator Proteins/analysis , Complement System Proteins/deficiency , Complement System Proteins/immunology , Epitopes , Humans , Lung/immunologyABSTRACT
The present work demonstrates that the injection of cysteine hydrochloride, a reducing agent, into animals has a pronounced effect on the character of immune response to proteinaceous antigen (bovine serum albumin): the formation of antibodies is enhanced, the synthesis of IgM is prevented from being changed over to the synthesis of IgG, the time of the circulation of free antigen is reduced and the time of their circulation in the blood is increased.
Subject(s)
Antigen-Antibody Complex/immunology , Cysteine/immunology , Immunity/drug effects , Acute Disease , Animals , Antibodies/analysis , Antigen-Antibody Complex/analysis , Antigens/analysis , Immunoglobulin G/biosynthesis , Immunoglobulin M/biosynthesis , Rabbits , Serum Albumin, Bovine/administration & dosage , Serum Albumin, Bovine/immunology , Serum Sickness/immunology , Time FactorsSubject(s)
Asthma/immunology , Bronchitis/immunology , Cryoglobulins/isolation & purification , Immunoglobulins/isolation & purification , Antigen-Antibody Complex/isolation & purification , Autoantigens/isolation & purification , Chronic Disease , Humans , Immunoglobulin A/isolation & purification , Immunoglobulin G/isolation & purification , Immunoglobulin M/isolation & purification , Lung/immunologyABSTRACT
Treatment of immune complexes consisting of different antigens and corresponding IgG with low doses of hydrochloric cystein led to the antibody inactivation, to the complex splitting, and to the release of the antigen. Antibodies being a part of the complex retained their capacity to react with the antiglobulin serum. The optimal doses of cystein leading to the complex splitting and to the IgG inactivation in the immune complex composition failed to act on unbound IgG. The effect of other reducing agents (glutathion and sodium sulfite) on the immune complex was similar to that of cystein. The differences in the effect of cystein on unbound and antigen-bound antibodies indicated that apparantly the combining site of antibody served as a point of cystein application.
